Early diagnosis of pre-T1D prior to overt hyperglycemia requires proof of impaired metabolism via lengthy oral glucose tolerance tests, creating a need to identify additional biomarkers involved in metabolism and/or immune dysregulation. We have identified insulin-like growth factor-1 (IGF-1) deficiency as a biomarker of pre-T1D and demonstrated that as a potential combination therapy, IGF-1 synergizes with low-dose IL-2 to promote regulatory T cell proliferation.
Publications
Melanie R. Shapiro, Leeana D. Peters, Matthew E Brown, C. Cabello-Kindelan, A. Posgai, A. Bayer, T. Brusko
bioRxiv, 2022
Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis
Melanie R. Shapiro, C. Wasserfall, S. Mcgrail, A. Posgai, Rhonda L. Bacher, Andrew B. Muir, M. Haller, D. Schatz, J. Wesley, M. V. von Herrath, W. Hagopian, C. Speake, M. Atkinson, T. Brusko
Diabetes, 2019
Pleiotropic roles of the insulin-like growth factor axis in type 1 diabetes.
Melanie R. Shapiro, M. Atkinson, T. Brusko
Current Opinion in Endocrinology, Diabetes & Obesity, 2019